LAA Closure

LAA Closure

A one-time Solution for Reducing the Risk of Stroke

The WATCHMAN LAA Closure devices offer a proven safe and effective option for reducing the risk of stroke in non-valvular AF patients.

  • WATCHMAN FLX is the next generation LAA closure device and is built on the proven clinical platform of WATCHMAN.
  • Closing the left atrial appendage reduces the risk of stroke as well as the long-term risk of bleeding which is associated with OAC in patients with non-valvular AF.
  • Long-term data from PROTECT-AF and PREVAIL demonstrated that WATCHMAN offered statistically significant reductions in disabling and fatal stroke, non-procedure-related major bleeding and mortality compared to warfarin after 5 years of follow-up.1
  • The PINNACLE FLX US IDE Clinical Trial showed WATCHMAN FLX safety and efficacy, meeting the primary safety endpoint with an 0.5% procedure-related event-rate and a primary endpoint of 100% effective closure rate at 12 months.2

Most studied LAAC device in the world

With over 20 years of LAAC innovation and experience, WATCHMAN has changed the lives of over 300,000 patients and has advanced the standard of care with proven, safe, and trusted patient outcomes. WATCHMAN FLX, the only device custom-engineered for the LAA, is a generation ahead and in a class all on its own.

Proven icon with check mark.

Proven

View clinical trials

Safe icon with heart in shield.

Safe1

View safety data

Effective icon with cog in arrows.

Effective1

View efficacy data
--:-- What is the evidence for Left Atrial Appendage Closure in stroke prevention?

Watch Now

What is the evidence for Left Atrial Appendage Closure in stroke prevention?

Proven Procedure

Learn about the efficacy results of WATCHMAN in clinical trials of patients with non-valvular AF, eligible or with contraindication to OAC therapy

Proven Procedure

See the efficacy data

Proven Safety

Review safety data from clinical studies and real-life registries

Proven Safety

See the safety data

Do you have a patient who may be a candidate for receiving the WATCHMAN FLX device?

Find an implant centre in your area

REFERENCES
* In non-valvular AF Patients
1. Reddy VY, 5-Year Outcomes After Left Atrial Appendage Closure From the PREVAIL and PROTECT AF Trials. J Am Coll Cardiol. 2017 Dec 19;70(24):2964-2975.
2. Doshi SK, et al. PINNACLE FLX Results Presented at HRS 2020.

CAUTION:
The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labelling supplied with each device.
Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries.
This material not intended for use in France.

Download the detailed brochure